AJM300, a novel oral antagonist of α4‐integrin, sustains an increase in circulating lymphocytes: A randomised controlled trial in healthy male subjects - Fukase, Hiroyuki; Kajioka, Toshifumi; Oikawa, Ichiro; Ikeda, Naoki; Furuie, Hidetoshi (British journal of clinical pharmacology, 2020)
Keywords: clinical trial; Original; pharmacodynamics; pharmacokinetics; Phase I; randomised controlled trial; clinical trial; pharmacokinetics; randomised controlled trial; Phase I; pharmacodynamics